RESUMEN
OBJECTIVE: The information concerning the morbidity and mortality of hereditary hemochromatosis is based primarily on clinical cohorts of symptomatic patients. The major aim of this study was to analyze the long-term prognosis for Swedish patients with this condition, with respect to both clinical features and survival, in relation to the route by which the disease was detected. PATIENTS AND METHODS: 373 patients with hemochromatosis detected through routine health check-ups (n = 153), family screening (n = 44), symptoms of arthralgia (n = 23), investigation of other diseases/symptoms (n = 108) or signs of liver disease (n = 45) were monitored for a mean period of 11.9 ± 5.8 years. The degree of liver fibrosis and survival were analyzed. RESULTS: Overall survival among these patients was not significantly different from that of a matched normal population. The patients diagnosed through health check-ups and family screening were detected at an earlier age and had the highest rate of survival. Liver biopsy at the time of diagnosis revealed cirrhosis in 9% of those detected through the health check-ups and 5% in the case of family screening, compared with 13% for the group with arthralgia, 17% for other diseases/symptoms and 42% for liver disease. CONCLUSION: Health check-ups and family screening allow detection of hereditary hemochromatosis at an earlier age and with less advanced liver fibrosis, although a few of these patients have already developed cirrhosis. Our study indicates that iron indices should be included in health check-ups, and if abnormal, should lead to further investigation.
Asunto(s)
Hemocromatosis/sangre , Hemocromatosis/diagnóstico , Antígenos de Histocompatibilidad Clase I/genética , Cirrosis Hepática/complicaciones , Cirrosis Hepática/patología , Proteínas de la Membrana/genética , Adulto , Anciano , Artralgia/complicaciones , Análisis Mutacional de ADN , Diagnóstico Precoz , Fatiga/complicaciones , Femenino , Ferritinas/sangre , Estudios de Seguimiento , Hemocromatosis/complicaciones , Hemocromatosis/genética , Proteína de la Hemocromatosis , Humanos , Hierro/sangre , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Examen Físico , Pronóstico , Modelos de Riesgos Proporcionales , Suecia , Transferrina/metabolismoRESUMEN
OBJECTIVES: Autoimmune hepatitis (AIH) is a liver disease which, if untreated, may lead to liver cirrhosis and hepatic failure. Limited data exist regarding factors predicting the long-term outcome. The aims of this study were to investigate symptoms at presentation, prognostic features, management and treatment in relation to long-term outcome of AIH. MATERIAL AND METHODS: A cohort of 473 Swedish patients with AIH was characterized regarding initial symptoms and signs, factors predicting death and future need for liver transplantation. Survival and causes of death were retrieved from Swedish national registers. RESULTS: At diagnosis, fatigue was a predominant symptom (69%), 47% of the patients were jaundiced and 30% had liver cirrhosis. Another 10% developed cirrhosis during follow-up. Markedly elevated alanine aminotransferase levels at presentation were correlated with a better outcome. A high international normalized ratio (INR) at diagnosis was the only risk factor predicting a need for later liver transplantation. Histological cirrhosis, decompensation and non-response to initial treatment were all factors that correlated with a worse outcome. Overall life expectancy was generally favourable. However, most deaths were liver-related, e.g. liver failure, shock and gastrointestinal bleeding. CONCLUSIONS: Cirrhosis at diagnosis, a non-response to initial immune-suppressive treatment or elevated INR values were associated with worse outcome and a need for later liver transplantation. In contrast, an acute hepatitis-like onset with intact synthetic capacity indicated a good response to treatment and favourable long-term prognosis. Lifetime maintenance therapy is most often required.
Asunto(s)
Hepatitis Autoinmune/terapia , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Causas de Muerte , Distribución de Chi-Cuadrado , Niño , Preescolar , Progresión de la Enfermedad , Femenino , Hepatitis Autoinmune/diagnóstico , Hepatitis Autoinmune/epidemiología , Humanos , Pruebas de Función Hepática , Trasplante de Hígado/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Pronóstico , Modelos de Riesgos Proporcionales , Sistema de Registros , Factores de Riesgo , Tasa de Supervivencia , Suecia , Resultado del TratamientoRESUMEN
BACKGROUND: The exact incidence and prevalence of Budd-Chiari syndrome (BCS) is unknown in the general population. Published reports differ in terms of the clinical characteristics, effects of therapy and survival. AIMS: To investigate the epidemiology, clinical presentation and survival in patients with BCS. METHODS: Retrospective multicentre study in Sweden reviewing the medical records of all patients with BCS 1986-2003, identified from the computerised diagnosis database of 11 hospitals, including all university hospitals and liver transplantation centres. RESULTS: Forty-three patients with BCS were identified, of whom nine (21%) had concomitant portal vein thrombosis. The mean age-standardised incidence and prevalence rates in 1990-2001 were calculated to be 0.8 per million per year and 1.4 per million inhabitants respectively. Myeloproliferative disorders (38%), thrombophilic factors (31%) and oral contraceptives (30%) were common aetiological factors. Two or more risk factors were present in 44%. In 23%, no risk factor was evident. The median follow-up time was 2.7 years. Seventy-two percent were on anticoagulant therapy during follow-up. Transjugular intrahepatic portosystemic shunting, surgical shunting procedures and liver transplantation were performed in 4, 6 and 18 patients respectively. Nineteen patients died. The overall transplantation-free survival at 1, 5 and 10 years was 47, 28 and 17% respectively. CONCLUSIONS: Budd-Chiari syndrome is a rare disorder; the mean age-standardised incidence and prevalence rates in Sweden in 1990-2001 were calculated to be 0.8 per million per year and 1.4 per million inhabitants respectively. The presence of a myeloproliferative disorder was a common aetiological factor in our cohort and about half of the patients had a multifactorial aetiology. The transplantation-free survival was poor.
Asunto(s)
Síndrome de Budd-Chiari/epidemiología , Síndrome de Budd-Chiari/etiología , Síndrome de Budd-Chiari/patología , Adolescente , Adulto , Anciano , Análisis Químico de la Sangre , Niño , Preescolar , Femenino , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Factores de Riesgo , Estadísticas no Paramétricas , Análisis de Supervivencia , Suecia/epidemiologíaRESUMEN
BACKGROUND & AIMS: The importance of genetic factors for the development of primary sclerosing cholangitis (PSC) is incompletely understood. This study assessed the risk of PSC and inflammatory bowel disease (IBD) among first-degree relatives of patients with PSC, compared with the first-degree relatives of a cohort without PSC. METHODS: Subjects from the national Swedish cohort of PSC patients (n = 678) were matched for date of birth, sex, and region to up to 10 subjects without a diagnosis of PSC (n = 6347). Linkage through general population registers identified first-degree relatives of subjects in both the PSC and comparison cohorts (n = 34,092). Diagnoses among first-degree relatives were identified by using the Inpatient Register. RESULTS: The risk of cholangitis was statistically significantly increased in offspring, siblings, and parents of the PSC patient cohort, compared with relatives of the comparison cohort, with the hazard ratios and 95% confidence intervals, 11.5 (1.6-84.4), 11.1 (3.3-37.8), and 2.3 (0.9-6.1), respectively. The hazard ratios for ulcerative colitis (UC) among first-degree relatives of all PSC patients was 3.3 (2.3-4.9) and for Crohn's disease 1.4 (0.8-2.5). The risk of UC for relatives of PSC patients without IBD was also increased, 7.4 (2.9-18.9). CONCLUSIONS: First-degree relatives of patients with PSC run an increased risk of PSC, indicating the importance of genetic factors in the etiology of PSC. First-degree relatives of PSC patients without IBD are also at an increased risk of UC, which might indicate shared genetic susceptibility factors for PSC and UC.
Asunto(s)
Colangitis Esclerosante/epidemiología , Colitis Ulcerosa/epidemiología , Predisposición Genética a la Enfermedad , Adolescente , Adulto , Estudios de Casos y Controles , Hijo de Padres Discapacitados , Femenino , Humanos , Masculino , Persona de Mediana Edad , SueciaRESUMEN
OBJECTIVE: Autoimmune hepatitis (AIH) is a chronic liver disease, which if untreated can lead to cirrhosis and hepatic failure. The aim of the study was to investigate the incidence, prevalence, diagnostic tradition and clinical initial presentation of AIH. MATERIAL AND METHODS: Analyses were performed in 473 patients identified as having probable or definite AIH. RESULTS: The incidence of AIH was 0.85/100,000 (95% CI 0.69-1.01) inhabitants, which is somewhat lower than reported previously. The point prevalence amounted to 10.7/100,000 (95% CI 8.8-13.1), and 76% of the cases were females. The age-related incidence curve was bimodal but men were found to have only one incidence peak in the late teens, whereas women had a peak after menopause. AIH was presented as a spectrum of clinical settings from detected "en passant" to acute liver failure. Almost 30% of patients already had liver cirrhosis at diagnosis. Autoantibodies indicative of AIH type 1 were found in 79% of cases. Other concomitant autoimmune diseases were frequently found (49%). CONCLUSIONS: The incidence and prevalence figures confirm that AIH is a fairly uncommon disease in the Swedish population. Symptoms at presentation were unspecific, but almost half of the patients were jaundiced, with around 30% having liver cirrhosis. The majority of Swedish AIH patients had AIH type 1.
Asunto(s)
Hepatitis Autoinmune/diagnóstico , Hepatitis Autoinmune/epidemiología , Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Incidencia , Masculino , Prevalencia , Estudios Retrospectivos , Suecia/epidemiologíaRESUMEN
BACKGROUND/AIMS: The causes of ulcerative colitis are unknown, although it is plausible that dietary factors are involved. Case-control studies of diet and ulcerative colitis are subject to recall biases. The aim of this study was to examine the prospective relationship between the intake of nutrients and the development of ulcerative colitis in a cohort study. METHODS: The study population was 260,686 men and women aged 20-80 years, participating in a large European prospective cohort study (EPIC). Participants were residents in the UK, Sweden, Denmark, Germany or Italy. Information on diet was supplied and the subjects were followed up for the development of ulcerative colitis. Each incident case was matched with four controls and dietary variables were divided into quartiles. RESULTS: A total of 139 subjects with incident ulcerative colitis were identified. No dietary associations were detected, apart from a marginally significant positive association with an increasing percentage intake of energy from total polyunsaturated fatty acids (trend across quartiles OR = 1.19 (95% CI = 0.99-1.43) p = 0.07). CONCLUSIONS: No associations between ulcerative colitis and diet were detected, apart from a possible increased risk with a higher total polyunsaturated fatty acid intake. A biological mechanism exists in that polyunsaturated fatty acids are metabolised to pro-inflammatory mediators.
Asunto(s)
Colitis Ulcerosa/etiología , Dieta/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Europa (Continente) , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios ProspectivosRESUMEN
BACKGROUND: Previously, we showed that colonic epithelium of ulcerative colitis (UC) patients expresses increased levels of mRNA for 3 antimicrobial peptides, human beta-defensin 2 (hBD-2), hBD-3, and hBD-4 compared to controls. METHODS: Human colon mucosa was analyzed using double immunofluorescence staining, in situ hybridization, immunoelectron microscopy, and quantitative real-time reverse-transcriptase polymerase chain reaction (qRT-PCR) with specific antibodies and probes in the respective assays. RESULTS: We demonstrate that lamina propria in colon from UC patients, Crohn's colitis patients, and controls contain cells that express hBD-2. These cells were identified as mature plasma cells by the highly specific CD138 marker, by their prominent IgA or IgG expression, and by their ultrastructural characteristics. By immunoelectron microscopy it was furthermore shown that the hBD-2 peptide was expressed in rough endoplasmic reticulum, the Golgi complex, and cytoplasmic vesicles, reflecting consecutive steps of synthesis and transport for secretion. Plasma cells were 2-3 times more abundant in UC colon than in control colon and Crohn's colitis. Moreover, plasma cells in UC colon expressed hBD-3 and hBD-4 mRNA. Additionally, hBD-2 mRNA expression was demonstrated in 3 out of 4 well-characterized plasma cell lines. CONCLUSIONS: Mature colonic plasma cells can express multiple beta-defensins. In UC, defensin production by plasma cells is probably clinically relevant since plasma cells accumulate in large numbers between the distorted crypts and muscularis mucosae, first focally than diffusely, so as to protect against microbial attack.
Asunto(s)
Colitis Ulcerosa/metabolismo , Colon/metabolismo , Enfermedad de Crohn/metabolismo , Células Plasmáticas/metabolismo , beta-Defensinas/biosíntesis , Adulto , Anciano , Anciano de 80 o más Años , Colitis Ulcerosa/inmunología , Colon/inmunología , Enfermedad de Crohn/inmunología , Femenino , Humanos , Inmunidad Innata , Hibridación Fluorescente in Situ , Mucosa Intestinal/inmunología , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología , Masculino , Microscopía Fluorescente , Microscopía Inmunoelectrónica , Persona de Mediana Edad , Células Plasmáticas/ultraestructura , Reacción en Cadena de la Polimerasa de Transcriptasa InversaAsunto(s)
Hepatitis Autoinmune/tratamiento farmacológico , Inmunosupresores/uso terapéutico , Corticoesteroides/uso terapéutico , Autoanticuerpos/sangre , Azatioprina/uso terapéutico , Carcinoma Hepatocelular/etiología , Hepatitis Autoinmune/complicaciones , Hepatitis Autoinmune/diagnóstico , Humanos , Neoplasias Hepáticas/etiología , Factores de RiesgoRESUMEN
Therapeutic monoclonal antibodies represent one of the fastest growing segments in the pharmaceutical market. The growth of the segment has necessitated development of new efficient and cost saving platforms for the preparation and analysis of early candidates for faster and better antibody selection and characterization. We report on a new integrated platform for automated harvesting of whole unclarified cell-culture broths, followed by in-line tandem affinity-capture, pH neutralization and size-exclusion chromatography of recombinant antibodies expressed transiently in mammalian human embryonic kidney 293T-cells at the 1-L scale. The system consists of two bench-top chromatography instruments connected to a central unit with eight disposable filtration devices used for loading and filtering the cell cultures. The staggered parallel multi-step configuration of the system allows unattended processing of eight samples in less than 24h. The system was validated with a random panel of 45 whole-cell culture broths containing recombinant antibodies in the early profiling phase. The results showed that the overall performances of the preparative automated system were higher compared to the conventional downstream process including manual harvesting and purification. The mean recovery of purified material from the culture-broth was 66.7%, representing a 20% increase compared to that of the manual process. Moreover, the automated process reduced by 3-fold the amount of residual aggregates in the purified antibody fractions, indicating that the automated system allows the cost-efficient and timely preparation of antibodies in the 20-200mg range, and covers the requirements for early in vitro and in vivo profiling and formulation of these drug candidates.
Asunto(s)
Anticuerpos Monoclonales/aislamiento & purificación , Animales , Técnicas de Cultivo de Célula/métodos , Cromatografía en Gel , Medios de Cultivo/química , Filtración/instrumentación , Células HEK293 , HumanosRESUMEN
The changes in PYY in several gastrointestinal disorders and their possible clinical implications are reviewed. The changes in PYY seem to be an adaptive response to alterations in the patho-physiological condition caused by the disease. This becomes evident in gastrointestinal disorders such as diabetes gastroenteropathy, inflammatory bowel diseases, celiac disease, systemic sclerosis and post-intestinal resection state. On the other hand, changes in PYY in chronic idiopathic slow transit constipation appear to be primary and could be one of the etiologic factors of the disease. PYY does not seem to be involved in colorectal carcinoma. Although gastrointestinal dysmotility in neuro-muscular diseases is evident, PYY is not affected. The changes in PYY in gastrointestinal disorders could be beneficial in clinical practice. Thus, in cases where an increase or decrease in PYY is desirable, a diet that increases or decreases PYY synthesis and release can be followed, or a receptor agonist or antagonist can be utilized.
Asunto(s)
Enfermedades Gastrointestinales/metabolismo , Péptido YY/metabolismo , Péptido YY/fisiología , Anorexia/metabolismo , Enfermedad Celíaca/metabolismo , Neoplasias Colorrectales/metabolismo , Humanos , Enfermedades Inflamatorias del Intestino/metabolismo , Enfermedades Neuromusculares/metabolismoRESUMEN
Chronic pancreatitis has an incidence of 3-8 new cases per 100,000 inhabitants and year. Alcohol is the most common cause. It is, however, not an independent risk factor but rather a co-factor. Smoking and genetic predisposition are increasingly regarded as causative factors. The diagnosis is today based mainly on history and findings at imaging tests. Pain treatment starts with NSAID-medication with or without paracetamol. Oral pancreatic enzyme therapy for pain should be tested early in the course. Endoscopic stent insertion into the main pancreatic duct can be used in selected cases. Operation is not recommended until other less invasive methods have been tested but should ideally be performed before addiction to opiates occurs. Oral enzyme supplementation is effective in the majority of cases with malnutrition. Most patients with chronic pancreatitis and diabetes need insulin treatment. Interdisciplinary specialist treatment teams should be established and take responsibility for diagnosis, assessment and interventional procedures (e.g. endoscopy, surgery). Due to the low incidence of the disease 3-4 such teams/centres seem appropriate in our country to allow a critical patient load.
Asunto(s)
Pancreatitis , Alcoholismo/complicaciones , Antiinflamatorios no Esteroideos/administración & dosificación , Enfermedad Crónica , Consenso , Endoscopía del Sistema Digestivo , Humanos , Trastornos Nutricionales/complicaciones , Dolor/diagnóstico , Dolor/cirugía , Manejo del Dolor , Conductos Pancreáticos/cirugía , Pancreatitis/diagnóstico , Pancreatitis/tratamiento farmacológico , Pancreatitis/etiología , Pancreatitis/cirugía , Grupo de Atención al Paciente , Guías de Práctica Clínica como Asunto , Stents , SueciaAsunto(s)
Fallo Hepático Agudo , Acetaminofén/envenenamiento , Adulto , Analgésicos no Narcóticos/envenenamiento , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Hepatitis/complicaciones , Humanos , Fallo Hepático Agudo/diagnóstico , Fallo Hepático Agudo/etiología , Fallo Hepático Agudo/terapia , Trasplante de Hígado , Persona de Mediana Edad , Planificación de Atención al Paciente , PronósticoAsunto(s)
Infecciones por Helicobacter/microbiología , Helicobacter pylori , Úlcera Gástrica/microbiología , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/clasificación , Helicobacter pylori/efectos de los fármacos , Helicobacter pylori/aislamiento & purificación , Humanos , Úlcera Gástrica/tratamiento farmacológicoAsunto(s)
Proteínas de la Matriz Extracelular/genética , Proteínas de Homeodominio/genética , Cirrosis Hepática/genética , Factores de Transcripción/genética , Animales , Progresión de la Enfermedad , Proteínas de la Matriz Extracelular/metabolismo , Proteínas de la Matriz Extracelular/fisiología , Expresión Génica , Costos de la Atención en Salud , Proteínas de Homeodominio/metabolismo , Proteínas de Homeodominio/fisiología , Humanos , Proteínas con Homeodominio LIM , Hígado/metabolismo , Hígado/patología , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/metabolismo , Cirrosis Hepática/patología , Ratones , Factores de Transcripción/metabolismo , Factores de Transcripción/fisiologíaRESUMEN
Patients with acute watery diarrhea caused by Vibrio cholerae O1 or enterotoxigenic Escherichia coli (ETEC) were analyzed for innate immune factors produced by the epithelium during the disease process. Duodenal biopsies were obtained from study participants at the acute (day 2) and convalescent (day 21) stages of disease. Levels of α-defensin (HD-5 and -6), ß-defensin (hBD-1-4), and cathelicidin (LL-37) mRNAs were determined by real-time qRT-PCR. hBD-2, HD-5, LL-37 peptides were analyzed in duodenal epithelium by immunomorphometry. Concentration of hBD-2 in stool was determined by ELISA. Specimens from healthy controls were also analyzed. hBD-2 mRNA levels were significantly increased at acute stage of diarrhea; hBD-2 peptide was detected in fecal specimens but barely in duodenal epithelium at acute stage. Immunomorphometry analysis showed that Paneth cells contain significantly higher amounts of HD-5 pre/propeptide at convalescence (P<0.01) and in healthy controls (P<0.001) compared to acute stage, LL-37 peptide levels also decreased at acute stage while mRNA levels remained unchanged. mRNA expression levels of the other antimicrobial peptides remained unchanged with higher levels of α-defensins than ß-defensins. V. cholerae induced an innate immune response at the acute stage of disease characterized by increased expression of hBD-2, and continued expression of hBD-1, HD-5-6, and LL-37.
Asunto(s)
Péptidos Catiónicos Antimicrobianos/análisis , Cólera/metabolismo , Diarrea/metabolismo , Escherichia coli Enterotoxigénica/fisiología , Infecciones por Escherichia coli/metabolismo , Vibrio cholerae O1/fisiología , Adulto , Animales , Péptidos Catiónicos Antimicrobianos/genética , Cólera/microbiología , Convalecencia , Diarrea/microbiología , Duodeno/metabolismo , Escherichia coli Enterotoxigénica/aislamiento & purificación , Infecciones por Escherichia coli/microbiología , Femenino , Cabras , Caballos , Humanos , Masculino , Ratones , Persona de Mediana Edad , Muramidasa/genética , Muramidasa/metabolismo , ARN Bacteriano/genética , ARN Ribosómico 18S/genética , Vibrio cholerae O1/aislamiento & purificación , Adulto JovenRESUMEN
BACKGROUND: The catechol-O-methyltransferase (COMT) enzyme has a key function in the degradation of catecholamines and a functional polymorphism is val158met. The val/val genotype results in a three to fourfold higher enzymatic activity compared with the met/met genotype, with the val/met genotype exhibiting intermediate activity. Since pain syndromes as well as anxiety and depression are associated to low and high COMT activity respectively and these conditions are all associated with irritable bowel syndrome (IBS) we wanted for the first time to explore the relationship between the polymorphism and IBS. METHODOLOGY/PRINCIPAL FINDINGS: 867 subjects (445 women) representative of the general population and 70 consecutively sampled patients with IBS (61 women) were genotyped for the val158met polymorphism and the IBS patients filled out the Hospital-Anxiety-and-Depression-Scale (HADS) questionnaire, and an IBS symptom diary. RESULTS: There was a significantly higher occurrence of the val/val genotype in patients compared with controls (30% vs 20%; Chi(2) (1) 3.98; pâ=â0.046) and a trend toward a lower occurrence of the val/met genotype in IBS patients compared with controls (39% vs 49%; Chi(2) (1) 2.89; pâ=â0.089). Within the IBS patients the val/val carriers exhibited significantly increased bowel frequency (2.6 vs 1.8 stools per day; Chi(2) (1) 5.3; pâ=â0.03) and a smaller proportion of stools with incomplete defecation (41% vs 68%; Chi(2) (1) 4.3; pâ=â0.04) compared with the rest (val/met+met/met carriers). The val/val carriers also showed a trend for a smaller proportion of hard stools (0% vs 15%; Chi(2) (1) 3.2; pâ=â0.08) and a higher frequency of postprandial defecation (26% vs 21%; Chi(2) (1) 3.0; pâ=â0.08). CONCLUSIONS/SIGNIFICANCE: In this study we found an association between the val/val genotype of the val158met COMT gene and IBS as well as to specific IBS related bowel pattern in IBS patients.